甲狀腺癌診斷市場規模、佔有率和成長分析：按診斷類型、癌症類型、應用、最終用戶、技術、分銷管道和地區分類－2026年至2033年產業預測

2024 年全球甲狀腺癌診斷市場價值為 30.1 億美元，預計到 2025 年將成長至 31.6 億美元，到 2033 年將成長至 47.1 億美元，在預測期（2026-2033 年）內複合年成長率為 5.1%。

受甲狀腺結節發病率上升和先進影像技術的應用推動，全球甲狀腺癌診斷市場正經歷顯著成長。分子檢測、超音波技術和細針穿刺細胞學是關鍵組成部分，這些技術均有助於早期診斷和改善治療效果。目前，甲狀腺癌診斷正從傳統細胞學轉向次世代定序，特別是基因表現分類，預計這將減少因切片檢查結果不確定而導致的不必要手術。此外，支付方式創新和技術進步的整合也加速了市場滲透，分子檢測的保險報銷比例提高，促進了醫療保健的成本效益。這一趨勢在發展中地區尤為明顯，這些地區更高的檢出率推動了診斷設備的在地化生產，並透過支持遠端病理診斷降低了成本。

全球甲狀腺癌診斷市場成長要素

全球甲狀腺癌診斷市場的主要促進因素之一是甲狀腺癌發病率在全球範圍內的上升，這導致對先進診斷技術的需求不斷成長。遺傳易感性、環境因素和生活方式的改變等因素都加劇了疾病的盛行率。此外，人們對早期檢測重要性的認知不斷提高以及醫療基礎設施的改善也推動了市場的發展。影像學和分子診斷技術的進步進一步提高了甲狀腺癌檢測的準確性和效率，促使人們增加對創新診斷解決方案的投資，並更加關注這些方案，以滿足不斷成長的患者群體的需求。

全球甲狀腺癌診斷市場面臨的限制因素

全球甲狀腺癌診斷領域的主要市場限制因素之一是先進診斷技術和流程的高成本。這種經濟障礙會限制病患的就醫途徑，尤其是在醫療預算有限的中低收入地區。此外，診斷測試的保險報銷可能不足以涵蓋全部費用，導致醫療機構不願採用最新的診斷技術。這可能導致診斷和治療延誤，對患者預後產生負面影響，並可能限制整體市場成長。成本、可近性和醫療政策之間的相互作用仍然是該行業面臨的一項重大挑戰。

全球甲狀腺癌診斷市場趨勢

在全球甲狀腺癌診斷市場，液態生物檢體的應用呈現顯著成長趨勢，這主要得益於採樣技術和分子表徵技術的進步。這種轉變使得生物標記的早期檢測成為可能，並透過持續監測來提高治療效果的評估。因此，市場對液態生物檢體檢測標準化的需求日益成長，這有助於診斷公司與臨床檢查室之間的合作，並提高檢測的可及性。臨床醫生被這些方法的一致性和減輕患者負擔的優勢所吸引，而商業夥伴則認知到透過整合核酸和蛋白質標記通路來最佳化工作流程的機會。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球甲狀腺癌診斷市場規模：依診斷類型分類

• 診斷影像
  • 超音波影像
  • CT影像
  • 磁振造影
  • 核子醫學掃描術診斷
  • 其他
• 基於切片檢查的診斷
• 分子診斷
• 臨床檢測
• 其他

全球甲狀腺癌診斷市場規模：依癌症類型分類

• 乳突甲狀腺癌
• 濾泡性甲狀腺癌
• 甲狀腺髓樣癌
• 未分化型甲狀腺癌

全球甲狀腺癌診斷市場規模：按應用領域分類

• 癌症早期發現
• 癌症分期
• 治療監測
• 復發監測
• 其他

全球甲狀腺癌診斷市場規模：按最終用戶分類

• 醫院
• 診斷檢查室
• 癌症研究機構
• 專科診所
• 其他

全球甲狀腺癌診斷市場規模：依技術分類

• 人工智慧驅動的診斷系統
• 次世代定序
• 基於PCR的診斷
• 免疫組織化學
• 其他

全球甲狀腺癌診斷市場規模：按分銷管道分類

• 直銷
• 診斷服務供應商
• 線上平台

全球甲狀腺癌診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Siemens Healthineers
• Danaher Corporation
• Illumina
• QIAGEN
• bioMerieux
• Agilent Technologies
• Becton Dickinson
• Hologic
• GE HealthCare
• Philips Healthcare
• Canon Medical Systems
• Fujifilm Holdings
• PerkinElmer
• Myriad Genetics
• Veracyte
• Exact Sciences
• NeoGenomics Laboratories

結論與建議

Global Thyroid Cancer Diagnostics Market size was valued at USD 3.01 Billion in 2024 and is poised to grow from USD 3.16 Billion in 2025 to USD 4.71 Billion by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).

The global market for thyroid cancer diagnostics is experiencing significant growth, driven by a rising incidence of thyroid nodules and the adoption of advanced imaging techniques that enhance diagnostic accuracy. Key components include molecular tests, ultrasound technology, and fine needle aspiration cytology, which facilitate timely diagnoses and better treatment outcomes. A shift from traditional cytology to next-generation sequencing, particularly the use of gene expression classifiers, has emerged to reduce unnecessary surgeries associated with indeterminate biopsy results. Furthermore, the integration of payment innovations and technological advancements is accelerating market penetration, as increased reimbursement for molecular tests promotes cost-efficient care. The trend is evident in developing regions, where heightened detection rates lead to local diagnostics production and reduced costs through telepathology support.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Thyroid Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Thyroid Cancer Diagnostics Market Segments Analysis

Global thyroid cancer diagnostics market is segmented by diagnostic type, cancer type, application, end user, technology, distribution channel and region. Based on diagnostic type, the market is segmented into Imaging Diagnostics, Biopsy-based Diagnostics, Molecular Diagnostics, Laboratory Testing and Others. Based on cancer type, the market is segmented into Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer and Anaplastic Thyroid Cancer. Based on application, the market is segmented into Early Cancer Detection, Cancer Staging, Treatment Monitoring, Recurrence Monitoring and Others. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Cancer Research Institutes, Specialty Clinics and Others. Based on technology, the market is segmented into AI-enabled Diagnostic Systems, Next-generation Sequencing, PCR-based Diagnostics, Immunohistochemistry and Others. Based on distribution channel, the market is segmented into Direct Sales, Diagnostic Service Providers and Online Platforms. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Thyroid Cancer Diagnostics Market

One of the key market drivers for the global thyroid cancer diagnostics market is the rising incidence of thyroid cancer worldwide, which has led to an increased demand for advanced diagnostic techniques. Factors such as genetic predisposition, environmental influences, and lifestyle changes are contributing to the growing prevalence of this disease. Additionally, heightened awareness about the importance of early detection and improved healthcare infrastructure are bolstering the market. Technological advancements in imaging and molecular diagnostics further enhance the accuracy and efficiency of thyroid cancer detection, driving investments and clinical focus on innovative diagnostic solutions to cater to the expanding patient population.

Restraints in the Global Thyroid Cancer Diagnostics Market

One significant market restraint in the global thyroid cancer diagnostics sector is the high cost associated with advanced diagnostic technologies and procedures. This financial barrier can limit accessibility for patients, especially in low- and middle-income regions where healthcare budgets are constrained. Moreover, the reimbursement policies for diagnostic tests may not adequately cover the expenses, deterring healthcare providers from adopting the latest diagnostic innovations. Consequently, this can lead to delays in diagnosis and treatment, negatively impacting patient outcomes and limiting overall market growth. Interaction between costs, accessibility, and healthcare policy remains a critical challenge for the industry.

Market Trends of the Global Thyroid Cancer Diagnostics Market

The Global Thyroid Cancer Diagnostics market is experiencing a significant trend towards the adoption of liquid biopsies, driven by advancements in sampling techniques and molecular characterization. This shift facilitates earlier detection of biomarkers and offers enhanced assessment of therapeutic efficacy through continuous monitoring. Consequently, there is a growing push for the standardization of liquid biopsy tests, fostering collaborations between diagnostics companies and clinical laboratories, which enhances accessibility. Clinicians are drawn to the consistency and reduced patient burden these methods provide, while business partners recognize opportunities for workflow optimization through the integration of nucleic acid and protein marker pathways.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Thyroid Cancer Diagnostics Market Size by Diagnostic Type & CAGR (2026-2033)

• Market Overview
• Imaging Diagnostics
  • Ultrasound Imaging
  • CT Imaging
  • MRI Imaging
  • Nuclear Imaging
  • Others
• Biopsy-based Diagnostics
• Molecular Diagnostics
• Laboratory Testing
• Others

Global Thyroid Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Papillary Thyroid Cancer
• Follicular Thyroid Cancer
• Medullary Thyroid Cancer
• Anaplastic Thyroid Cancer

Global Thyroid Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Early Cancer Detection
• Cancer Staging
• Treatment Monitoring
• Recurrence Monitoring
• Others

Global Thyroid Cancer Diagnostics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Specialty Clinics
• Others

Global Thyroid Cancer Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• AI-enabled Diagnostic Systems
• Next-generation Sequencing
• PCR-based Diagnostics
• Immunohistochemistry
• Others

Global Thyroid Cancer Diagnostics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Diagnostic Service Providers
• Online Platforms

Global Thyroid Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Diagnostic Type, Cancer Type, Application, End User, Technology, Distribution Channel)
  • US
  • Canada
• Europe (Diagnostic Type, Cancer Type, Application, End User, Technology, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnostic Type, Cancer Type, Application, End User, Technology, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnostic Type, Cancer Type, Application, End User, Technology, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnostic Type, Cancer Type, Application, End User, Technology, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veracyte
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations